NIH PAR · NIAID · K22
PAR-25-251: NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
- NOFO number
- PAR-25-251
- Type
- PAR
- Activity code
- K22
- Primary institute
- NIAID · National Institute of Allergy and Infectious Diseases
- Clinical trials
- Not Allowed
- Posted
- Dec 3, 2024
- Opens
- Jan 12, 2025
- Expires
- Jan 8, 2028
PAR-25-251 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 12, 2025 | March 12, 2025 * | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| June 12, 2025 | July 12, 2025 * | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| October 12, 2025 | November 12, 2025 * | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| February 12, 2026 | March 12, 2026 * | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 12, 2026 | July 12, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 12, 2026 | November 12, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 12, 2027 | March 12, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 12, 2027 | July 12, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 12, 2027 | November 12, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-251
NIH RePORTER lists 1 project funded under PAR-25-251 in FY2022–FY2026, with $162K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$162K
Award dollars under PAR-25-251, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 1 | 1 | $162K |
Institutions with the most funding
- Augustana University$162K · 1 project
Funding institutes
- NIAID$162K · 1
Activity codes funded
- K221 record
Most recent new awards
- HIV-induced HNRNP SUMOylation in the splicing of viral and host mRNAs (opens NIH RePORTER)
Augustana University · 1K22AI197912-01 · NIAID · Notice Sep 17, 2026
$162KK22
What its predecessor PAR-22-075 funded
PAR-25-251 reissues PAR-22-075. Its funding history is the best guide to who wins under this program: 31 projects and $7.3M in FY2022–FY2026.
Projects funded
31
Distinct projects, FY2022–FY2026
New awards
31
Type 1 (new project) award records
NIH funding
$7.3M
Award dollars under PAR-22-075, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 11 | 11 | $1.8M |
| FY2025 | 23 | 12 | $3.1M |
| FY2026 | 19 | 8 | $2.5M |
Institutions with the most funding
- Johns Hopkins University$540K · 2 projects
- Clemson University$515K · 2 projects
- University of Pittsburgh at Pittsburgh$324K · 2 projects
- Icahn School of Medicine at Mount Sinai$270K · 1 project
- University of Arizona$270K · 1 project
- Indiana University Indianapolis$270K · 1 project
- Univ of North Carolina Chapel Hill$270K · 1 project
- University of Texas Hlth Sci Ctr Houston$270K · 1 project
Funding institutes
- NIAID$7.3M · 53
Activity codes funded
- K2253 records
Most recent new awards
- Investigating mucosal and peripheral immune correlates of protection against pediatric influenza virus (opens NIH RePORTER)
University of Pittsburgh at Pittsburgh · 1K22AI187532-01A1 · NIAID · Notice Sep 1, 2026
$162KK22
- Therapeutically Targeting Kinases in KSHV Disease (opens NIH RePORTER)
University of Nebraska Medical Center · 1K22AI192774-01 · NIAID · Notice Aug 11, 2026
$160KK22
- Cognate CD4+ T cell help to macrophages during tuberculosis (opens NIH RePORTER)
State University New York Stony Brook · 1K22AI192592-01 · NIAID · Notice Jul 17, 2026
$162KK22
- Decoding Host Immunometabolic Control of Viral Persistence for Zoonotic Pathogens (opens NIH RePORTER)
University of Vermont & St Agric College · 1K22AI192590-01 · NIAID · Notice Jun 30, 2026
$162KK22
- Anti-inflammatory effects of reverse transcriptase inhibitors during bacterial infection (opens NIH RePORTER)
Loyola University Chicago · 1K22AI192772-01 · NIAID · Notice Apr 2, 2026
$159KK22
- Elucidating the role of genome organization in cDC1 development (opens NIH RePORTER)
University of Rochester · 1K22AI184752-01 · NIAID · Notice Apr 1, 2026
$162KK22
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-251. Contact the program officer at the institute that fits your research before applying.
- NIAID · National Institute of Allergy and Infectious Diseases
- none
Related notices
Apr 13, 2026 · NOT-AI-26-001
Notice of Change to Research Support and Salary Restrictions in PAR-25-251, NIAID Career Transition Award K22 Independent Clinical Trial Not Allowed) .
Jan 28, 2026 · NOT-OD-26-029
NIH Removing AIDS Application Due Dates from NOFOs. See Notice NOT-OD-26-029.
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply - Application Guide provides details on these application types.
- Award budget
- Information
- Project period
- The Phase II project period may not exceed 2 years. Other
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-075.
Other open NOFOs for K22
- PAR-25-215Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)NINDS · next due Feb 12, 2027
- PAR-25-216Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)NINDS · next due Feb 12, 2027
- PAR-25-027NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)NIDCR · next due Feb 12, 2027
- PAR-24-209NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)NHLBI
- PAR-24-211NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)NHLBI
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.